Navigation Links
Diabetes drug shows promise in reducing Alzheimer's disease in an experimental model
Date:3/24/2014

(Boston) Researchers from Boston University School of Medicine (BUSM) have found that the diabetic drug, pramlintide, reduces amyloid-beta peptides, a major component of Alzheimer's disease (AD) in the brain and improves learning and memory in two experimental AD models. These findings, which appear online in Molecular Psychiatry, also found AD patients have a lower level of amylin in blood compared to those without this disease. These results may provide a new avenue for both treatment and diagnosis of AD.

AD is a degenerative brain disease associated with severe functional decline and has no effective treatment. Currently there are 5 million people with Alzheimer's disease in the U.S. alone, and the cost of caring for these patients exceeds $100 billion per year. If no effective treatments are developed, the number of Alzheimer's patients is expected to grow to 14-16 million by the year 2050.

There are multiple reasons for the high costs and high failure rates associated with developing potential new drugs for AD. One factor is that most drugs do not penetrate into the brain making them ineffective for treating AD; another is that it usually takes 10-15 years to develop a new target drug to prove the safety and efficacy. According to senior author Wendy Qiu, MD, PhD, associate professor of psychiatry and pharmacology & experimental therapeutics at BUSM, in contrast, some existing drugs for other diseases may penetrate into brain and may be effective for Alzheimer's disease. "Unfortunately most pharmaceuticals are reluctant to support this type of repurposing research because of limited financial benefit and some patent limitation, even though the cost is much less expensive and the development time is much shortened," she added.

Using AD models, the BUSM researchers investigated the effects of amylin on the pathogenesis of the disease. "Surprisingly, injections of amylin or pramlintide into the AD models reduced the amyloid burden as well as lowered the concentrations of amyloid-beta peptides (Aβ), a major component of AD in the brain," explained Qiu. Pramlintide is an analog of a natural occurring peptide, amylin, produced by the pancreas. "It can easily cross the blood/brain barrier and has shown favorable safety profile for diabetes patients," she added.

According to the researchers, including lead author Haihao Zhu, MD, PhD, also from the department of pharmacology & experimental therapeutics at BUSM, these results argue for a therapeutic application of amylin-class peptides for AD. "There is broad agreement that more therapeutic avenues need to be explored in addition to targeting Aβ for the treatment of AD. Amylin-class drugs not only remove Aβ from the brain, as demonstrated by our study, but also can improve glucose metabolism and cerebrovasculature in the AD brain," said Qiu. Based on their findings the researchers propose that amylin-class peptides have potential to become a new avenue as a challenge test for diagnosis of AD and as well as a therapeutic for the disease. If the clinical trial proves the effect of pramlintide for Alzheimer's disease, Qiu believes this drug can be applied to Alzheimer's patients in only three to five years.


'/>"/>
Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Obesity and diabetes have adverse effects on cancer outcomes
2. Ottawa researchers find new pathway connected to type 2 diabetes
3. New findings show link between diabetes and pancreatic cancer
4. Gestational diabetes linked to increased risk for heart disease in midlife
5. NYU researchers find majority of Latinas are unaware of their risk of diabetes
6. Epigenetic changes could explain type 2 diabetes
7. Nobelist James Watson proposes an unconventional view of type 2 diabetes causation
8. Type 1 diabetes: Vitamin D deficiency occurs in an early stage
9. Editorial illustrates shift away from glycemic control in diabetes treatment
10. A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
11. Future directions for landmark diabetes study in journal Diabetes Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology: